Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivablesReceivables - NetShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanofi (SNY) Receivables (2016 - 2024)

Historic Receivables for Sanofi (SNY) over the last 17 years, with Q2 2025 value amounting to $8.8 billion.

  • Sanofi's Receivables fell 353.23% to $8.8 billion in Q2 2025 from the same period last year, while for Jun 2025 it was $8.8 billion, marking a year-over-year decrease of 353.23%. This contributed to the annual value of $9.7 billion for FY2024, which is 879.13% down from last year.
  • Per Sanofi's latest filing, its Receivables stood at $8.8 billion for Q2 2025, which was down 353.23% from $9.7 billion recorded in Q4 2024.
  • Sanofi's Receivables' 5-year high stood at $10.6 billion during Q4 2023, with a 5-year trough of $8.2 billion in Q2 2021.
  • Its 5-year average for Receivables is $9.3 billion, with a median of $9.2 billion in 2024.
  • In the last 5 years, Sanofi's Receivables soared by 750.98% in 2023 and then plummeted by 830.15% in 2024.
  • Sanofi's Receivables (Quarter) stood at $9.6 billion in 2021, then grew by 3.46% to $9.9 billion in 2022, then grew by 7.28% to $10.6 billion in 2023, then dropped by 8.3% to $9.7 billion in 2024, then decreased by 9.32% to $8.8 billion in 2025.
  • Its last three reported values are $8.8 billion in Q2 2025, $9.7 billion for Q4 2024, and $9.2 billion during Q2 2024.